TrialInvestigational new drugs2013

Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer.

Robert Jones et al.PubMed ↗Publisher ↗

No numbers read from the abstract.